Latest Amferia News & Updates

See the latest news and media coverage for Amferia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amferia

Antimicrobial peptide technology developer

amferia.com

Headquarters: Mölndal, Sweden
Founded year: 2018
Company type: Private company
Number of employees: 2–20

Last updated Today

Latest news about Amferia

In short: Amferia achieved FDA De Novo approval for its antibacterial wound dressing and secured €3.5M in funding to accelerate global commercialization.

Company announcements

June 16 Amferia

Amferia appoints two new board members for global expansion

Randy Schwartz and Nikolaj Sørensen bring expertise in wound care commercialization and life science strategy.

April 29 Amferia

Amferia seeks partners post-FDA De Novo approval

The approval creates a new category for its peptide-based antibacterial wound dressing. Amferia attends EWMA Congress to discuss U.S. market expansion.

April 16 Amferia

Amferia signs distribution contract with Interchem for Ireland

The partnership introduces AMP Wound Dressing to Irish veterinary professionals in Spring 2026, expanding Amferia's European presence.

February 21 Amferia

Amferia gains recognition as top wound care company

Featured in SmartTRAK article on antimicrobial wound care future. Recent FDA De Novo approval highlighted.

Media coverage

February 12 Ny Teknik

Milestone: Innovation from Chalmers gets green light in the USA - kills bacteria

The American drug agency FDA has approved an antibacterial wound dressing from the Chalmers spin-off Amferia. Thus, the company is free to enter the American...

27 November 2025 Breakit

Amferia co-founder named New Entrepreneur of the Year (Årets Nybyggare) by the Swedish King

Atefyekta is a co-founder of Amferia, a medical device company that has developed a breakthrough technology using anti-microbial peptides to combat the rapid rise of...

17 March 2024 Life Science Sweden

Stronger cash position takes Amferia further in the fight against resistant bacteria

Amferia is developing a new antibacterial material that is to be used in healthcare for, among other things, wound care, and is to be effective against many different types of...

17 March 2024 Dagens Juridik

Lindahl advisor when Amferia enters agreement with Orkla Wound Care

Law firm Lindahl has assisted Amferia AB in entering into an exclusive private label license and supply agreement within animal health with Orkla Wound Care. The agreement - which...

Never miss news about Amferia

Track Amferia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.